
Drs Stephanie Christenson and Jean Bourbeau explore the role of type 2 inflammation in Chronic Obstructive Pulmonary Disease (COPD).
Join leading experts Miguel Lanz, Lakshi Aldredge, Angela Bretton, and Hilary Ugras in an engaging case-based discussion that explores the interconnected nature of chronic underlying type 2 inflammation and its profound impact across multiple diseases.

This cross-TA plenary session addressed challenges in type 2 inflammation-driven diseases. Esteemed faculty, including Profs Klaus Rabe, Sharon Dell, Anju Peters, Milli Gupta, Eric Simpson, Stella Lee, and moderator Oscar Palomares, discussed strategies to enhance quality of life, reduce disease burden, and prioritize patient-centered care.
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.
How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

Watch highlights from the AAAAI 2023 Conference in San Antonio, TX, USA.
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.

Highlights from the ADVENT symposium at the Inflammatory Skin Disease Summit (ISDS) 2023 exploring the role of type 2 inflammation in atopic dermatitis.
Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 inflammation and barrier dysfunction contribute to the development of atopic comorbidities and increased susceptibility to infections.
Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies